Heptares to Moderate Panel on Rare Diseases at BBC New York CEO Meeting (13-14 February)
WELWYN GARDEN CITY, England and BOSTON, February 8, 2013 /PRNewswire/ –
Heptares Therapeutics, the leading GPCR drug discovery company, announces that its
President, Dan Grau, will attend the Boston Biotech Conference New York CEO Meeting
[http://bbbiotechconference.com/conference-details.php?id=13 ] taking place on 13-14
February at Apella in New York City, NY, USA, at which he will moderate a panel on Rare
Diseases (3:30pm EST, 14 February).
For a full list of events at which Heptares will be present, please visit
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically
challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked
to a wide range of human diseases. Leveraging our advanced structure-based drug design
technology platform, we have built an exciting discovery and development pipeline of novel
drug candidates, which have the potential to transform the treatment of serious diseases,
including Alzheimer’s disease, Parkinson’s disease, schizophrenia, migraine and diabetes.
Our pharmaceutical partners include Shire, AstraZeneca, MedImmune, Takeda and Cubist, and
we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and
Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.
SOURCE Heptares Therapeutics